Successful track record of developing and commercializing innovative and clinically significant healthcare technologies.
President and Chief Executive Officer
Scott brings nearly 20 years of executive experience in the medical device industry, having both founded and helmed numerous companies in the healthcare space.
After graduating from Dartmouth College with Bachelor of Arts and Bachelor of Engineering degrees, Scott began his career as an infantry officer in the 82nd Airborne Division.
Following his military service, he began his medical device career as a sales representative for a surgical distributor. After identifying a need in the healthcare supply chain space, he co-founded and led CentriMed before the company was acquired by Global Healthcare Exchange. Scott next founded and led Innovative Spinal Technologies for eight years before the company was sold. He led the $100m Americas geography of Systagenix, a private equity acquisition of the J&J Advanced Wound Care Division.
More recently, Scott He has served as a president and consultant to numerous boards and CEOs across a wide variety of companies in the medical device, biologics and related markets. He has raised over $120m in public and private equity investments and also the co-inventor of six patents.
Chief Compliance Officer, Executive Vice President Clinical, Regulatory and Quality Affairs and Chief Compliance Officer
Brian is an accomplished senior compliance executive with more than 25 years of experience in the medical device, pharmaceutical and biologics industries.
He began his career in the United States Army as a nuclear weapons specialist and has experience working for Johnson & Johnson, Covidien and Quintiles.
In 2002, Brian founded EEC & Associates, a global compliance consulting company providing clinical, regulatory and quality services to domestic and international life science companies. More recently, Brian was Executive Vice President of Clinical, Quality and Regulatory Affairs at Histogenics Corporation and was instrumental in raising $49 million to restart the NeoCart Pivotal Phase III study.
Chief Financial Officer
Jim Murphy is an accomplished senior finance executive with more than 30 years of experience in high-growth domestic and international environments and extensive experience in the life science sector.
Prior to joining GI Dynamics, he served as CFO of OXiGENE, Inc., and CFO of HemaSure, Inc. As part of a global team at Whatman Plc, he was instrumental in the sale of HemaSure assets to Whatman, including the consolidation of its worldwide operating locations from eighteen to nine.
Karl Blohm, Ph.D.
Vice President, International Operations
Karl is a seasoned strategic commercial executive and general manager with more than 20 years of medical device industry experience combining capital equipment and medical devices in both large and small company environments.
Karl previously served as partner and general manager of AB Medica France, a national medical technology distribution company that he helped establish. Karl has also played a key in successfully launching several innovative medical devices and technologies in his previous positions at EndoGastric Solutions, Accuray Europe and Siemens. Karl also holds a Ph.D. in physics from the University of Paris.